FDA advisers back updating COVID shots to target JN.1 virus family
2024-06-06
疫苗信使RNA
A group of advisers to the Food and Drug Administration on Wednesday unanimously recommended that COVID-19 vaccinesCOVID-19 vaccines be updated to cover coronavirus strains with a family known as JN.1 ahead of the fall.
The committee, which had originally been scheduled to meet in mid-May, supported targeting the JN.1 lineage broadly, rather than some specific subvariants that are now more prevalent in the U.S. Their recommendation matches the advice of the World Health Organization, which in April also recommended COVID shots cover the JN.1 family.
According to documents prepared by FDA staff, a JN.1 offshoot known as KP.2 has been the dominant variant in the U.S. since April. Both the broader lineage and KP.2 are distinct from the XBB virus variants that vaccines currently target.
Committee members argued that aiming vaccines at JN.1 would be effective, although some did express concern the unpredictability of viral evolution could blunt the potency of an updated shot.
“Having a vaccine that [covers] part of the trunk of the tree rather than the branches makes sense to me,” said Melinda Wharton, a panel member and associate director for vaccine policy at the National Center for Immunization and Respiratory Diseases. “I think the chances of having broad cross-protection are probably greater, and I am concerned about not potentially having all the vaccine platforms available.”
At the meeting, Pfizer, Moderna and Novavax each presented animal model data, and said they could make updated formulations of their shots available in time for fall vaccination campaigns. Novavax’s vaccine, which unlike Pfizer’s and Moderna’s messenger RNA shots is protein-based, takes longer to adapt and manufacture, however.
Several panelists felt that having a third option was important for people who may be hesitant to receive an mRNA shot — a view that was shared by Peter Marks, head of the FDA office that reviews vaccines.
“As I understood the comment from Novavax, if the KP.2 strain was selected, they would not necessarily deliver the vaccine on time,” said Mark Sawyer, a committee member and professor of clinical pediatrics at the University of California, San Diego. “And I think that at this point is a major problem ... [the vaccine] needs to be equitably available to everybody at the same time.”
The agency isn’t required to follow the advice of its committees, but it usually does.
Ruth Link-Gelles, an epidemiologist with the Centers for Disease Control and Prevention, said an upcoming CDC panel could consider whether individuals might need an additional shot if they received one before a peak in cases.
'
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。